Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 4 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Kymera Therapeutics INC paid sponsored hires in similar roles1 certified filing for “Senior Director, Pharmacovigilance Operations” (Regulatory Affairs Managers) in MA: $280k–$280k, median $280k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 4 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Kymera Therapeutics INC paid sponsored hires in similar roles
- 1 certified filing for “Senior Director, Pharmacovigilance Operations” (Regulatory Affairs Managers) in MA: $280k–$280k, median $280k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Who we are:
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn .
How we work:
• PIONEER : We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
• COLLABORATE : We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
• BELONG : We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.
How you’ll make an impact:
The Senior Director, Outcomes, Value & Access will serve as Kymera’s strategic leader for health economics, real-world evidence (RWE), value communication, and payer-relevant medical strategy across the pipeline. Reporting to the VP of Medical Affairs, this role will shape and execute the company’s integrated outcomes and access strategy to support optimized patient access, informed clinical decision-making, and successful product commercialization. The ideal candidate is an experienced HEOR leader with deep immunology expertise (dermatology and/or respiratory strongly preferred), a proven track record preparing for and supporting launches, and significant experience engaging national and regional payer stakeholders.
• Strategic and forward-thinking, with the ability to translate scientific evidence into compelling value narratives.
• Highly collaborative, diplomatic, and influential across functions and levels.
• Strong communicator with exceptional scientific and business acumen.
• Comfort working in a dynamic, rapidly growing biotech setting.
Strategic Leadership & Vision
• Lead the development and execution of Kymera’s Medical Outcomes, Value & Access strategy across the immunology portfolio.
• Serve as a core member of the Medical Affairs Team, advising on evidence generation, clinical strategy, and payer-relevant insights.
• Drive cross-functional alignment on value strategy across Medical Affairs, HEOR, Market Access, Clinical Development, Regulatory, Commercial, and Global teams.
Health Economics & Outcomes Research (HEOR)
• Oversee HEOR strategy, including economic modeling, treatment-pattern studies, and comparative-effectiveness analyses.
• Guide development and validation of economic models (e.g., budget impact, cost-effectiveness) to support payer decision-making.
• Lead creation of AMCP dossiers, value narratives, and scientific payer resources.
Real-World Evidence & Data Generation
• Design and oversee RWE plans, including study concept refinement, protocol development, external data partnerships, and post-marketing evidence strategy.
• Partner with Clinical Development and Data Science teams to integrate outcomes-focused endpoints into clinical trial design.
Payer & External Stakeholder Engagement
• Build and maintain relationships with U.S. payer organizations, HTAs, integrated delivery networks, and employer groups to communicate clinical and economic value.
• Lead scientific exchange wit
Apply on employer site ↗